Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) – Research analysts at Wedbush reduced their FY2022 earnings per share estimates for Compass Therapeutics in a report released on Thursday, November 10th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.38) per share for the year, down from their previous forecast of ($0.36). The […]
